PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
−0.27%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.23
- Revenue estimate
- $1.3M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.24
- EPS estimate
- -$0.26
- Revenue actual
- $1.2M
- Revenue estimate
- $2.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $8.00
- PT range
- $7.00 – $9.00
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026